SLC35F4: A Potential Drug Target for Psychiatric Disorders (G341880)

Target Name: SLC35F4

NCBI ID: G341880

SLC35F4

SLC35F4: A Potential Drug Target for Psychiatric Disorders

SLC35F4 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and pancreas. It is a member of the sodium-dependent chloride transport gene family (SLC) and is responsible for transmitting electrical signals along the outer membrane of neurons and other excitable cells.

SLC35F4 is also known as OTTHUMP00000245812, which is a unique protein code. It is expressed in the brain and is involved in the regulation of neuronal excitability and synaptic plasticity. The SLC35F4 protein is thought to play a crucial role in the transmission of electrical signals along the outer membrane of neurons, which are critical for the function and survival of these cells.

Recent studies have suggested that SLC35F4 may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This is because the SLC35F4 protein is involved in the regulation of neuronal excitability and synaptic plasticity, which are thought to be involved in the development and progression of these disorders.

One of the reasons why SLC35F4 is considered a potential drug target is its involvement in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Studies have shown that SLC35F4 is involved in the regulation of synaptic plasticity, including the formation of new neural connections and the modulation of existing ones. This suggests that SLC35F4 may be a useful target for disorders that are characterized by changes in synaptic plasticity, such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which SLC35F4 may be involved in the development of psychiatric disorders is its role in the regulation of neuronal excitability. Studies have shown that SLC35F4 is involved in the regulation of neuronal excitability, including the maintenance of normal ion channels and the regulation of the flow of electrical signals through the brain. This suggests that SLC35F4 may be a potential target for disorders that are characterized by changes in neuronal excitability, such as schizophrenia.

In addition to its potential role as a drug target or biomarker, SLC35F4 is also considered a promising candidate for the development of new therapies for various psychiatric and neurological disorders. For example, studies have shown that SLC35F4 may be a potential target for the treatment of Alzheimer's disease, as it is thought to be involved in the regulation of the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. Similarly, SLC35F4 may also be a potential target for the treatment of Parkinson's disease, as it is thought to be involved in the regulation of the movement of muscles and the brain.

Overall, SLC35F4 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of sodium-dependent chloride transport and neuronal excitability. Its potential as a drug target or biomarker for various psychiatric and neurological disorders makes it an important area of research and may lead to new and effective therapies for the treatment of these disorders.

Protein Name: Solute Carrier Family 35 Member F4

Functions: Putative solute transporter

The "SLC35F4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35F4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets